



SDI FINAL EVALUATION FORM 1.1

PART 1:

Journal Name:	Journal of Advances in Medicine and Medical Research
Manuscript Number:	Ms_JAMMR_49377
Title of the Manuscript:	The effect of phosphodiesterase type5 inhibitors on the development of retinopathy of prematurity: A Randomized Clinical Trial

PART 2:

FINAL EVALUATOR'S comments on revised paper (if any)	Authors' response to final evaluator's comments
<p>1.What is Ahvaz? If it is a Hospital state the name in full including where it is located</p> <p>2 Move the statement in line 26 to 22, its part of the study design, not a result.. Line 22 should start with "There was no differences....."</p> <p>3. In line 203 , you should open with what Sildenafil is...and its primary use. The pharmacological partway of Sildenafil must be explained alongside the pathophysiology of ROP in DISCUSSION.</p> <p>4, So what is the recommendation? Do we use the drug in patients with ROP with or without caution?. Write at list, a line statement on recommendation</p>	

Reviewer Details:

Name:	<i>Barbie o. M. Ejukonemu</i>
Department, University & Country	<i>College of Health Science, Bayero University, Kano, Nigeria</i>